The IPO Buzz: UpStream Bio (UPB Proposed) Launches $200 Million IPO
UpStream Bio (UPB Proposed) unveiled the terms and launched its $200 million IPO early today – Monday, Oct. 7, 2024. The Phase II biotech, whose leading drug candidate is targeting severe asthma, chronic rhinosinusitis with nasal polyps, and COPD, is offering 12.5 million shares at a price range of $15.00 to $17.00 to raise $200 […]
October 7, 2024 Read More